<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="(PWID) in Mozambique. This information is critical to ensure the" exact="treatment" post="necessary to decrease the progression of liver disease and"/>
 <result pre="the transmission of both HIV and hepatitis. We assess the" exact="prevalence" post="of HIV, HBV and HCV co-infections as well as"/>
 <result pre="Maputo and Nampula/Nacala, two large urban centers of Mozambique. Rapid" exact="screening" post="of HIV, HBV (HBsAg) and HCV was performed on"/>
 <result pre="median age was 32â€‰years [IQR: 27â€&quot;36]. HIV, HBV and HCV" exact="prevalence" post="were respectively 44.9% (95% CI:37.6â€&quot;52.3), 32.8% (95% CI:26.3â€&quot;39.5) and"/>
 <result pre="that include needle exchange programs and integrated services for the" exact="diagnosis" post="and treatment of HIV, HBV and HCV to address"/>
 <result pre="needle exchange programs and integrated services for the diagnosis and" exact="treatment" post="of HIV, HBV and HCV to address these epidemics"/>
 <result pre="to strengthen ART coverage in the population as an important" exact="treatment" post="strategy for both viruses. Keywords People who inject drugs"/>
 <result pre="among the most vulnerable to HIV infection, with an estimated" exact="prevalence" post="of 17.8% globally and 8.3% in the Sub-Saharan African"/>
 <result pre="are considered a key population for targeted HIV prevention and" exact="treatment" post="efforts due to their illicit drug use and associated"/>
 <result pre="[2, 3]. HIV ranks among one of the highest HIV" exact="prevalence" post="rates among adults aged 15â€&quot;49â€‰years old age (13.2%), largely"/>
 <result pre="been a lack of information about the population size, HIV" exact="prevalence" post="and their utilization of health services [5]. To address"/>
 <result pre="and 2014, using respondent-driven sampling (RDS). This study estimated HIV" exact="prevalence" post="at 50.1% in Maputo (95% CI: 40.1â€&quot;59.0) and 19.9%"/>
 <result pre="high prevalence, high burden of morbidity and mortality, and suboptimal" exact="diagnosis" post="and management approaches [8â€&quot;10]. Viral hepatitis are the most"/>
 <result pre="resulting in high morbidity and mortality rates [11, 12]. HIV" exact="infection" post="affects the natural course of hepatitis B virus (HBV)"/>
 <result pre="[2, 9â€&quot;11]. The BBS among PWID in Mozambique estimated HBV" exact="prevalence" post="at 32.1 and 36.4%, and HCV prevalence at 44.6"/>
 <result pre="Mozambique estimated HBV prevalence at 32.1 and 36.4%, and HCV" exact="prevalence" post="at 44.6 and 7.0%, in Maputo and Nampula/Nacala respectively."/>
 <result pre="infections have been established [15, 16]. Strengthening the prevention and" exact="treatment" post="of substance abuse, including narcotic drug abuse, is listed"/>
 <result pre="yet there continues to be lack of integrated prevention and" exact="treatment" post="services [18, 19]. In a country with one of"/>
 <result pre="19]. In a country with one of the highest HIV" exact="prevalence" post="rates in the world, understanding the epidemiology of HIV,"/>
 <result pre="critical in order to design effective and efficient prevention and" exact="treatment" post="programs. Neglecting to implement targeted services has the potential"/>
 <result pre="viral hepatitis. Since Mozambique has one of the highest HIV" exact="prevalence" post="rates in the world, neglecting to implement targeted services"/>
 <result pre="has been widely used among hard-to-reach populations to estimate HIV" exact="prevalence" post="and associated risk factors, and also to evaluate access"/>
 <result pre="rapid tests for HIV, HBV and HCV. The HIV rapid" exact="testing" post="procedures adhered to the national algorithm using Determineâ&quot;¢ HIV-1/2"/>
 <result pre="results, were used to estimate HIV prevalence. On-site rapid HBV" exact="testing" post="was done using Alere DetermineÂ® HbsAg (Abbott Laboratories, UK),"/>
 <result pre="HbsAg (Abbott Laboratories, UK), to detect surface antigen, and HCV" exact="testing" post="used SD Bioline HCV (Standard Diagnostics, Korea). Participants with"/>
 <result pre="respectively; none of the tests were able to determine if" exact="infection" post="was acute or chronic. Participants with positive results for"/>
 <result pre="assessment, where trained teams were ready to link them to" exact="treatment" post="services [6, 7]. Dried Blood Spot (DBS) were also"/>
 <result pre="(Murex Biotech Limited, UK) and were used to estimate HBV" exact="prevalence" post="in the survey; centralized HCV testing was not performed"/>
 <result pre="used to estimate HBV prevalence in the survey; centralized HCV" exact="testing" post="was not performed because a serologic anti-HCV assay using"/>
 <result pre="1684 in Maputo and 520 in Nampula. These RDS-adjusted pooled" exact="prevalence" post="estimates and 95% confidence intervals (CI) were obtained using"/>
 <result pre="HBV, HCV and co-infections As presented in Table 2, HIV" exact="prevalence" post="among participants was 44.9% (95% CI: 37.6â€&quot;52.3). The prevalence"/>
 <result pre="HIV prevalence among participants was 44.9% (95% CI: 37.6â€&quot;52.3). The" exact="prevalence" post="of HBsAg among PWID was 32.8% (95%CI: 26.3â€&quot;39.5) and"/>
 <result pre="co-infection was found in 29.5% (95%CI: 22.2â€&quot;36.8) of PWID. Triple" exact="infection" post="of HIV/HBV/HCV was identified in 9.2% (95%CI: 3.7â€&quot;14.7) of"/>
 <result pre="a Denominator reflects the number of participants who consented to" exact="testing" post="for each biomarker Associated risk factors for HIV/HBV and"/>
 <result pre="HBV (32.8%) or HCV (38.3%), which is substantially higher than" exact="prevalence" post="rates estimated for PWID reported from sub-Saharan African region"/>
 <result pre="the three infections at 18.3, 3.7, 21.8%, respectively [1]. Our" exact="prevalence" post="of HIV/HBV co-infection (13.1%) fall within the range observed"/>
 <result pre="based-on tenofovir (TDF), lamivudine (3TC) and efavirenz (EFV) has dual" exact="treatment" post="benefits for both HBV and HIV infections [9, 12,"/>
 <result pre="for both HBV and HIV infections [9, 12, 27]. The" exact="prevalence" post="of HIV/HCV co-infection among PWID participants found in this"/>
 <result pre="in this study (29.5%) was substantially higher than the estimated" exact="prevalence" post="in the sub-Saharan region (5.7%). Only a few studies"/>
 <result pre="evidence that HIV is associated with a higher risk of" exact="infection" post="with HCV due to the similar mode of transmission"/>
 <result pre="blood [29, 30]. In this study, we found that the" exact="prevalence" post="of HIV/HBV and HIV/HCV co-infection among PWID increased with"/>
 <result pre="with HIV/HCV co-infection are less likely to clear acute HCV" exact="infection" post="and more likely to transmit the virus which is"/>
 <result pre="before linkage to more comprehensive healthcare services. Clients receive point-of-care" exact="screening" post="for HIV, hepatitis, syphilis, tuberculosis and referrals for clinical"/>
 <result pre="opioid substitution therapy (OST); HIV services (including HIV prevention counseling," exact="testing" post="an ART); prevention and treatment of STIs; prevention, diagnosis"/>
 <result pre="services (including HIV prevention counseling, testing an ART); prevention and" exact="treatment" post="of STIs; prevention, diagnosis and treatment of TB and"/>
 <result pre="counseling, testing an ART); prevention and treatment of STIs; prevention," exact="diagnosis" post="and treatment of TB and viral hepatitis (B and"/>
 <result pre="an ART); prevention and treatment of STIs; prevention, diagnosis and" exact="treatment" post="of TB and viral hepatitis (B and C), risk"/>
 <result pre="integrated harm reduction package to prevent both HIV and hepatitis" exact="infection" post="among PWID, given their similar mode of transmission via"/>
 <result pre="similar mode of transmission via sexual exposure and high-burden of" exact="infection" post="in specific populations [9, 36, 41]. Efforts to promote"/>
 <result pre="(9.4% of the sample), perhaps due an absence of point-of-care" exact="testing" post="or treatment options within the national health care system"/>
 <result pre="the sample), perhaps due an absence of point-of-care testing or" exact="treatment" post="options within the national health care system at the"/>
 <result pre="the time of survey implementation, which may underestimate the true" exact="prevalence" post="of HCV in the population. Conclusions This was the"/>
 <result pre="that they have no competing interests. References References 1.DegenhardtLPeacockAColledgeSLeungJGrebelyJVickermanPet al.Global" exact="prevalence" post="of injecting drug use and sociodemographic characteristics and prevalence"/>
 <result pre="al.Global prevalence of injecting drug use and sociodemographic characteristics and" exact="prevalence" post="of HIV, HBV, and HCV in people who inject"/>
 <result pre="from: https://globalhealthsciences.ucsf.edu/sites/globalhealthsciences.ucsf.edu/files/pub/pwid-final-report-20180329.pdf.. Accessed 28 Feb 2020. 7.SemÃ¡ BaltazarCHorthRBootheMSathaneIYoungPChitsondzo LangaDet al.High" exact="prevalence" post="of HIV, HBsAg and anti-HCV positivity among people who"/>
 <result pre="MozambiqueBMC Infect Dis2019191102231791273 8.UmutesiJSimmonsBMakuzaJDDushimiyimanaDMbituyumuremyiAUwimanaJMet al.Prevalence of hepatitis B and C" exact="infection" post="in persons living with HIV enrolled in care in"/>
 <result pre="in RwandaBMC Infect Dis2017217 9.Bagheri AmiriFMostafaviEMirzazadehAHIV, HBV and HCV Coinfection" exact="prevalence" post="in Iran - a systematic review and meta-analysisPLoS One20163111(3)"/>
 <result pre="hepatitis B and C among people who inject drugs: high" exact="prevalence" post="of HIV and hepatitis C RNA positive infections observed"/>
 <result pre="mortality among HIV-positive individualsAIDS.201731182525253228926400 13.ViegasEOTembeNMacovelaEGonÃ§alvesEAugustoOIsmaelNet al.Incidence of HIV and the" exact="prevalence" post="of HIV, hepatitis B and syphilis among youths in"/>
 <result pre="Corte Real R, Mabunda N, Maueia C, et al. HBV" exact="infection" post="in untreated HIV-infected adults in Maputo, Mozambique. PLoS One."/>
 <result pre="from: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.Â Accessed 28 Feb 2020. 16.UNAIDS. 90â€&quot;90â€&quot;90 an ambitious" exact="treatment" post="target to help end the AIDS epidemic. Geneva: 2014."/>
 <result pre="in HIV-infected individuals: a systematic review and meta-analysis of estimated" exact="prevalence" post="in AfricaJ Int AIDS Soc20169119 31.EdwardJWing. The aging population"/>
 <result pre="DW, Mpondo BCT, Bakshi FA, Jaka H. Hepatitis B virus" exact="infection" post="in Tanzania: current status and challenges. J Trop Med."/>
 <result pre="from: http://alternatives-humanitaires.org/wp-content/uploads/2019/03/AH_N10_3_Focus_5_MSF_VEN.pdf. Accessed 5 Feb 2020. 38.TunWSheehyMBrozDOkalJMuraguriNRaymondHFet al.HIV and STI" exact="prevalence" post="and injection behaviors among people who inject Drugs in"/>
</results>
